MHNCS 2026 – J&J and Bicara face off
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
Karyopharm investors fasten their seatbelts
A binary Xpovio catalyst is set for March.
ASCO-GU 2026 – late-breakers in focus
Welireg, Padcev, and a surprise fillip for Flare.
Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
AbbVie scales back its GARP ambitions
After a phase 3 push the livmoniplimab plan falters.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
